ArticleBMJ public health2025
Cross-sectional analysis of cannabis use at work in the USA: differences by occupational risk level and state-level cannabis laws.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the prevalence of workplace cannabis use, including by state-level cannabis laws, occupational risk and medical cannabis use. Methods: Data are cross-sectional from wave 6 (2023) of the International Cannabis Policy Study (ICPS) and include 26 458 respondents aged 16-65 years from the USA. Separate regression models were run analysing workplace cannabis use across: (1) state-level cannabis laws and occupational risk, (2) reasons for cannabis use and (3) medical cannabis authorisation. All models were adjusted for sociodemographic characteristics. Results: Overall, 7.4% of workers and 21.5% of past 12-month cannabis consumers reported using cannabis at or within 2 hours of starting work in the last 30 days. Workplace cannabis consumption was highest among workers in states with 'recreational' cannabis laws (8.5%) compared with states with medical (6.3%; adjusted OR (AOR)=1.45, p=0.006) or illegal laws (6.2%; AOR=1.06, p=0.005). Workers in high-risk jobs were more likely to use cannabis at work (11.4%) than those in lower risk jobs (5.8%; AOR=1.58, p<0.001). Workplace cannabis use was also greater among cannabis consumers who use cannabis for medical versus recreational (29.4% vs 15.6%; AOR=2.35, p<0.001) or mixed reasons (24.2%; AOR=1.78, p=0.007); the same was true for consumers who reported having medical cannabis authorisation (39.0%) versus those without authorisation (17.4%; AOR=2.66, p<0.001). Conclusions: Reported cannabis use at work was most prevalent in states with recreational legalisation, particularly among individuals with medical cannabis authorisation and those who work higher risk jobs. Longitudinal research should examine the individual and occupational-level factors associated with workplace cannabis use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.